Skip to main content
Clinical Trials/NCT03349242
NCT03349242
Completed
Not Applicable

Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

MeiraGTx UK II Ltd8 sites in 3 countries140 target enrollmentDecember 19, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Retinitis Pigmentosa
Sponsor
MeiraGTx UK II Ltd
Enrollment
140
Locations
8
Primary Endpoint
Analysis of retinal structure and function to assess disease progression
Status
Completed
Last Updated
last year

Overview

Brief Summary

The rod-cone dystrophies (often referred to as retinitis pigmentosa (RP)) are a clinically and genetically heterogeneous group of disorders in which there is progressive loss of rod and later cone photoreceptor function leading to severe visual impairment. RP usually occurs as an isolated retinal disorder, but it may also be seen in association with systemic abnormalities.

Detailed Description

X-linked Retinitis Pigmentosa (XLRP) is a severe form of RP with early onset of nyctalopia and progression to legal blindness by the 3rd to 4th decade. Most affected males show symptomatic night blindness before the age of 10 years, are often myopic and show fundus abnormalities and ERG changes in early childhood. Examination of close female relatives is helpful in the absence of a family history, as the recognition of the XL carrier state will confirm the diagnosis.

Registry
clinicaltrials.gov
Start Date
December 19, 2017
End Date
April 19, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Males \& Females aged 5 years or older
  • Have RPGR-associated retinal dystrophy
  • Are able to give informed consent or assent, with the guidance of their parent/guardian where appropriate
  • Are able to undertake age-appropriate clinical assessments as specified in the protocol
  • Have genetic mutation within the RPGR gene confirmed by an accredited lab or research lab.

Exclusion Criteria

  • Are unable or unwilling to undertake consent or clinical testing

Outcomes

Primary Outcomes

Analysis of retinal structure and function to assess disease progression

Time Frame: 6 years

Retinal structure will be measured using Adaptive optics and SD-OCT and Fundal autofluorescence.

Secondary Outcomes

  • Retinal Structural detailed phenotyping(6 years)
  • Retinal Sensitivity(6 years)
  • Fundus Autofluorescence(6 years)
  • Visual Fields testing(6 years)

Study Sites (8)

Loading locations...

Similar Trials